126种新药进医保！
<div class="wx_rich_media_content" id="jsWxContainer"><p data-mpa-powered-by="yiban.io"><span class="wxart_image" wx-style='display:inline-block;text-align: center;font-size: var(--articleFontsize);letter-spacing: 0.034em;width: 100%;'></span><br></p><section style='line-height: 2em;'><span style='color: rgb(158, 7, 54);'><strong><span style='font-size: 17px; letter-spacing: 0.034em;'>126种新药进医保 2023年国家医保药品目录</span></strong><strong><span style='font-size: 17px; letter-spacing: 0.034em;'>发</span><span style='letter-spacing: 0.034em; font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;'>布</span></strong></span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'>2023年国家医保药品目录13日在京发布，此次调整共有126个药品新增进入国家医保药品目录，1个药品被调出目录，谈判或竞价成功的药品价格平均降幅61.7%。新版医保药品目录内药品总数达到3088种，其中西药1698种、中成药1390种；中药饮片仍为892种。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'> 国家医保局医药服务管理司司长黄心宇介绍，共有143个目录外药品参加谈判或竞价，其中121个药品谈判或竞价成功，谈判成功率为84.6%。成功率和价格降幅均与2022年基本相当。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><strong><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'><span style='letter-spacing: 0.034em; color: rgb(0, 122, 170);'>新版医保药品目录新增了抗肿瘤、罕见病、抗病毒等领域的药品，如治疗I型戈谢病成年患者的酒石酸艾格司他、用于治疗卡斯特曼病的司妥昔单抗、治疗复发或难治滤泡性淋巴瘤的林普利塞等。糖尿病等慢性病领域也有药品被纳入，如针对Ⅱ型糖尿病患者的多格列艾汀等。</span></span></strong><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'><span style='letter-spacing: 0.034em; color: rgb(0, 122, 170);'></span></span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'> 据介绍，此次调整在加强研究论证、广泛征求意见的基础上，进一步完善规则、规范程序，目录调整的科学性、规范性、透明度以及精细化水平等进一步提升。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'> “我们牢牢把握‘保基本’的功能定位，将基金承受能力作为必须坚守的底线，尽力而为、量力而行，着力满足广大参保人基本用药需求。”黄心宇表示，通过完善续约规则，初步建立基本覆盖新药全生命周期的支付标准形成机制，加大对医药创新的支持力度。同时，此次调整在确保基金安全的基础上，继续适当放宽部分目录内品种的支付范围，药品可及性和用药公平性得到进一步提升。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'> 国家医保局成立以来，已连续6年开展药品目录调整工作，累计将744个药品新增进入国家医保药品目录，同时将一批疗效不确切、临床易滥用的或被淘汰的药品调出目录，引领药品使用端发生深刻变化。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'> 中国药学会相关统计结果显示，自2018年以来，医保药品在医疗机构药品使用占比逐年上升，主导地位进一步巩固，临床用药合理性得到积极改善。同时，创新药进入医保速度明显加快，常用药品价格水平显著下降，重大疾病和特殊人群用药保障水平大幅提升，降低了群众用药负担。</span></section><section style='text-align: justify; margin-bottom: 24px; text-indent: 0em; line-height: 2em;'><strong><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'><span style='letter-spacing: 0.034em; color: rgb(0, 122, 170);'>新版国家医保药品目录以及国家医保谈判药品配备情况，可以在国家医保局微信公众号、国家医保局官方网站查询。</span></span></strong><span style='font-size: 17px;letter-spacing: 0.034em;text-decoration: none solid rgba(0, 0, 0, 0.9);'><span style='letter-spacing: 0.034em; color: rgb(0, 122, 170);'></span></span></section><section style='outline: 0px; max-width: 100%; box-sizing: border-box; color: rgb(34, 34, 34); letter-spacing: 0.544px; font-family: -apple-system, BlinkMacSystemFont, Arial, sans-serif; font-size: 16px; visibility: visible; overflow-wrap: break-word !important;'><section><section style='margin-top: 10px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;justify-content: center;display: flex;flex-flow: row nowrap;visibility: visible;overflow-wrap: break-word !important;'><section style='margin-right: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: middle;width: auto;flex: 100 100 0%;height: auto;align-self: center;border-width: 0px;visibility: visible;overflow-wrap: break-word !important;'><section powered-by="xiumi.us" style='outline: 0px;max-width: 100%;box-sizing: border-box;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;box-sizing: border-box;background-color: rgb(152, 186, 189);height: 1px;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;'><svg viewBox="0 0 1 1" style='float: left;line-height: 0;width: 0px;vertical-align: top;visibility: visible;'></svg></section></section></section></section><section style='outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: top;width: auto;flex: 0 0 0%;height: auto;line-height: 0;z-index: 3;visibility: visible;overflow-wrap: break-word !important;'><section powered-by="xiumi.us" style='outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 16px;height: 16px;vertical-align: top;overflow: hidden;border-width: 1px;border-style: solid;border-color: rgb(152, 186, 189);border-radius: 26px;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;'><svg viewBox="0 0 1 1" style='float: left;line-height: 0;width: 0px;vertical-align: top;visibility: visible;'></svg></section></section></section></section><section style='margin-left: -8px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: top;width: auto;flex: 0 0 0%;height: auto;line-height: 0;visibility: visible;overflow-wrap: break-word !important;'><section powered-by="xiumi.us" style='outline: 0px;max-width: 100%;box-sizing: border-box;text-align: left;justify-content: flex-start;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 16px;height: 16px;vertical-align: top;overflow: hidden;background-color: rgb(251, 228, 151);border-width: 0px;border-style: none;border-color: rgb(62, 62, 62);border-radius: 26px;visibility: visible;overflow-wrap: break-word !important;'><section style='outline: 0px;max-width: 100%;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;'><svg viewBox="0 0 1 1" style='float: left;line-height: 0;width: 0px;vertical-align: top;visibility: visible;'></svg></section></section></section></section></section><section><section><section powered-by="xiumi.us"><h1 data-darkmode-bgcolor="rgb(36, 36, 36)" data-darkmode-color="rgb(168, 168, 168)" data-style='max-width: 100%; color: rgb(62, 62, 62); font-family: 微软雅黑; letter-spacing: 0.5px; line-height: 25.6px; box-sizing: border-box !important; overflow-wrap: break-word !important;' style='color: rgb(122, 116, 116); outline: 0px; letter-spacing: 0.544px; text-align: right;'><section style='outline: 0px;text-align: left;line-height: 1.75em;'><span style='outline: 0px;font-size: 12px;color: rgb(136, 136, 136);'>来源：新华社</span></section></h1></section></section></section></section></section><p style='display: none;'><mp-style-type data-value="3"></mp-style-type></p><br>转载声明：本文转载自「微孝天下」，搜索「weixiaotianxia0712」即可关注，[<a target="_blank" href="https://mp.weixin.qq.com/s/wmvuXEU3lCSAeJKWbY0x-w">阅读原文</a>]。</div>
页:
[1]